Abstract:Background: Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct clinical and biological features and differential treatment responses have been identified using latent class analysis (LCA) in seven individual cohorts. To facilitate bedside identification of subphenotypes, clinical classifier models using readily available clinical variables have been described in four randomised controlled trials. We aimed to assess the performance of these models in observational cohorts of ARDS. Methods: In this observational, multicohort, retrospective study, we validated two machine-learning clinical classifier models for assigning ARDS subphenotypes in two observational cohorts of patients with ARDS: Early Assessment of Renal and Lung Injury (EARLI; n=335) and Validating Acute Lung Injury Markers for Diagnosis (VALID; n=452), with LCA-derived subphenotypes as the gold standard. The primary model comprised only vital signs and laboratory variables, and the secondary model comprised all predictors in the primary model, with the addition of ventilatory variables and demographics. Model performance was assessed by calculating the area under the receiver operating characteristic curve (AUC) and calibration plots, and assigning subphenotypes using a probability cutoff value of 0·5 to determine sensitivity, specificity, and accuracy of the assignments. We also assessed the performance of the primary model in EARLI using data automatically extracted from an electronic health record (EHR; EHR-derived EARLI cohort). In Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE; n=2813), a multinational, observational ARDS cohort, we applied a custom classifier model (with fewer variables than the primary model) to determine the prognostic value of the subphenotypes and tested their interaction with the positive end-expiratory pressure (PEEP) strategy, with 90-day mortality as the dependent variable. Findings: The primary clinical classifier model had an area under receiver operating characteristic curve (AUC) of 0·92 (95% CI 0·90-0·95) in EARLI and 0·88 (0·84-0·91) in VALID. Performance of the primary model was similar when using exclusively EHR-derived predictors compared with manually curated predictors (AUC=0·88 [95% CI 0·81-0·94] vs 0·92 [0·88-0·97]). In LUNG SAFE, 90-day mortality was higher in patients assigned the hyperinflammatory subphenotype than in those with the hypoinflammatory phenotype (414 [57%] of 725 vs 694 [33%] of 2088; p<0·0001). There was a significant treatment interaction with PEEP strategy and ARDS subphenotype (p=0·041), with lower 90-day mortality in the high PEEP group of patients with the hyperinflammatory subphenotype (hyperinflammatory subphenotype: 169 [54%] of 313 patients in the high PEEP group vs 127 [62%] of 205 patients in the low PEEP group; hypoinflammatory subphenotype: 231 [34%] of 675 patients in the high PEEP group vs 233 [32%] of 734 patients in the low PEEP group). Interpretation: Classifier models using clinical variables alone can accurately assign ARDS subphenotypes in observational cohorts. Application of these models can provide valuable prognostic information and could inform management strategies for personalised treatment, including application of PEEP, once prospectively validated. Funding: US National Institutes of Health and European Society of Intensive Care Medicine.

Time to change diagnostic criteria of ARDS: toward the disease entity-based subgrouping

Identification of Three Classes of Acute Respiratory Distress Syndrome Using Latent Class Analysis

Acute respiratory distress syndrome:new definition and progress

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Consensus statements on the utility of defining ARDS and the utility of past and current definitions of ARDS--protocol for a Delphi study

Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Recent advances in the understanding and management of ARDS

[Challenges in Clinical Diagnosis of Acute Respiratory Distress Syndrome].

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Acute respiratory distress syndrome

Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis

Opportunities for improved clinical trial designs in acute respiratory distress syndrome

[New 2023 Global Definition of Acute Respiratory Distress Syndrome: Progress and Limitation].

[Diagnosis and significance of ARDS]

Enhancing-ARDS diagnostics for ICU patients: a retrospective, nested case-control study to develop a biomarker-based model

A Retrospective, Nested Case-Control Study to Develop a Biomarker-Based Model for ARDS Diagnostics

The Acute Respiratory Distress Syndrome in 2013

An Expanded Definition of Acute Respiratory Distress Syndrome: Challenging the Status Quo.

Identifying risk factors for acute respiratory distress syndrome in critically ill patients: a retrospective study

Advances in Biomarkers for Diagnosis and Treatment of ARDS